Paul L Hess

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:1127-33. 2013
  2. ncbi request reprint Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    J Cardiovasc Electrophysiol 24:664-71. 2013
  3. ncbi request reprint Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:828-35. 2013
  4. ncbi request reprint Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 126:625-32.e1. 2013
  5. pmc Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Curr Cardiol Rep 15:330. 2013
  6. ncbi request reprint Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Clin Cardiol 35:649-57. 2012
  7. pmc Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?
    Sana M Al-Khatib
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 6:108-16. 2013
  8. ncbi request reprint Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials
    Patrick H Pun
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am J Kidney Dis 64:32-9. 2014

Detail Information

Publications8

  1. ncbi request reprint Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes?
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:1127-33. 2013
    ..A 2008 expert consensus statement recommended an in-person follow-up visit between 2 and 12 weeks after the placement of a new cardiovascular implantable electronic device (CIED)...
  2. ncbi request reprint Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    J Cardiovasc Electrophysiol 24:664-71. 2013
    ..Practice guidelines recommend the use of ICDs in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≤ 35% in the absence of contraindications...
  3. ncbi request reprint Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials
    Paul L Hess
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Heart Rhythm 10:828-35. 2013
    ..Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown...
  4. ncbi request reprint Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation
    Paul L Hess
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 126:625-32.e1. 2013
    ..Patients with atrial fibrillation often have cardiovascular risk factors or known comorbid disease, yet the use of evidence-based primary and secondary prevention cardiac therapy among atrial fibrillation outpatients is unknown...
  5. pmc Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715, USA
    Curr Cardiol Rep 15:330. 2013
    ..107 (95 % confidence interval 0.069-0.163). Prospective studies, particularly among patients not meeting traditional CRT criteria, are needed...
  6. ncbi request reprint Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims
    Paul L Hess
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
    Clin Cardiol 35:649-57. 2012
    ..Warfarin use and associated outcomes in patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device have not been described previously...
  7. pmc Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?
    Sana M Al-Khatib
    Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    Circ Arrhythm Electrophysiol 6:108-16. 2013
    ..A 2008 expert consensus statement outlined the minimum frequency of follow-up of patients with cardiovascular implantable electronic devices (CIEDs)...
  8. ncbi request reprint Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials
    Patrick H Pun
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am J Kidney Dis 64:32-9. 2014
    ..The benefit of a primary prevention implantable cardioverter-defibrillator (ICD) among patients with chronic kidney disease is uncertain...